Updated
The most significant concentration Kestra Medical Technologies, Lt discloses is ASSURE WCD, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Kestra Medical Technologies, Lt’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'We expect that revenues from our ASSURE WCD and associated products and services delivered as part of our Cardiac Recovery System platform will continue to account for nearly all of our revenue'”
“10-K Item 1A: 'We derive nearly all our revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations'”
“10-K Item 1: 'We rely on a single or limited number of suppliers for certain components of our ASSURE WCD.'”
Kestra's concentration is nearly complete across product, payor and supply, and all three exposures are high-share. Revenues from the ASSURE WCD and associated products and services delivered as part of the Cardiac Recovery System platform are expected to continue to account for nearly all of revenue. The company is effectively a single-product business, so any clinical, competitive, regulatory or adoption setback for that device would reach the whole top line. Payors compound this. Nearly all revenue comes from direct billing of third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations. Reimbursement rates, coverage decisions and claims processing therefore determine cash conversion, and the company has limited ability to set its own pricing. On the supply side, it relies on a single or limited number of suppliers for certain components of the ASSURE WCD. This is the most idiosyncratic of the three: a disruption at one vendor could halt production of the only revenue-generating product. Netting these out, the exposures are stacked rather than offsetting. Product and payor concentration set the structural baseline, while the component dependency is the likeliest source of a sudden operating shock. No diversification elsewhere in the filing cushions any of them.
For the engine’s reasoning on KMTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| KMTS● | Kestra Medical Technologies, Lt | 3 | 0 | 0 | 3 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
| ANGO | AngioDynamics, Inc. | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.